publication date: Jul. 11, 2014
20140711 - Jul. 11, 2014
ISSUE 28 – JULY 11, 2014PDF



NCI to Implement More Transparent Formula
For Calculating Cancer Center Support Grants

NCI took another step toward adopting a new formula for determining the size of cancer center support grants, with the National Cancer Advisory Board accepting a report from a working group that has been working on the problem since the fall of 2012. 

The schema proposed by the working group was accepted by the advisory board at its meeting June 23. It recommends broad organizing principles rather than specific numbers. 

After the Plenary
Don Berry: In NeoALTTO & ALTTO Trials, Neoadjuvant Response Predicts Adjuvant

An article in the June 6 issue of The Cancer Letter described plenary presentations at ASCO 2014. One presentation was the adjuvant breast cancer clinical trial ALTTO in HER2-positive disease, which “was chosen [for the plenary session] because it addressed the reliability of pathological complete response as a surrogate for patient benefit.”  

photoCounterpoint
George Sledge Responds To Berry’s Letter: Neoadjuvant Doesn’t Predict Adjuvant In Breast Cancer

As always, I both enjoyed and learned something interesting from Dr. Don Berry, one of the great biostatisticians of our era. I find, reading his analysis of ALTTO and NeoALTTO, much that I agree with. I am certainly no statistician, and must bow to his statistical analysis of ALTTO and NeoALTTO. And yet at the same time I think it misses the point. So I will beg to differ.

Also: Don Berry’s Rejoinder

photoAACR Changes Its Logo— For the Fifth Time Since 2000

The American Association for Cancer Research ushered in the year 2000 with a round logo that combined the lamp of knowledge with a map of the Americas and an aspirational slogan in Latin.

The 26-year-old logo gave way to one that looked more corporate. However, AACR didn’t stop at just one redesign. It changed the logo four more times. 

photoNIH Funding Opportunity
Outstanding Investigator Award In Cancer Research Available

The NIH has published a funding opportunity announcement for the Outstanding Investigator Award in any area of cancer research.

photoIn Brief

  • Three appointed to leadership positions at St. Jude

  • Duke’s Amy Abernethy named chief medical officer at Flatiron Health

  • William Hogan joins University of Florida as director of bioinformatics

  • J. Alan Diehl named associate director of basic sciences at MUSC

  • Vincent O’Neill named chief medical officer of Exosome Diagnostics

  • Joseph Haywood named president of FASEB

  • Thomas Jefferson University receives $110 million gift

  • Stand Up to Cancer Canada launched

  • Bristol-Myers Squibb announces collaboration with Duke University

  • Pew Charitable Trusts announce class of cancer research scholars

  • Steven Bangert named CEO of the Year by the American Cancer Society

photoDrug Development

  • Breakthrough Therapy designation granted to CTL019 in ALL

  • European Commission approves Halaven for metastatic breast cancer

  • Breakthrough Therapy designation granted to blinatumomab in Ph- ALL

  • Mylan launches generic Carboplatin Injection in multi-dose vials

Copyright (c) 2018 The Cancer Letter Inc.